Future challenges for microsomal transport protein inhibitors

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 277-286

  Wierzbicki, Anthony S ^a   Hardman, Tim ^b   Prince, William T ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Niche Science and Technology Ltd   (United Kingdom)

^c Surface Logix Inc   (United States)

Author keywords

Cardiovascular risk; Cholesterol; Drug development; Hepatic steatosis; Microsomal transfer protein; Triglyceride

Indexed keywords

ACETYLSALICYLIC ACID; AEGR 733; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; ATORVASTATIN; BAY 13 9953; CARRIER PROTEIN; CP 346086; DOUBLE STRANDED RNA; EZETIMIBE; FLAVONOID; GARLIC EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE; JTT 130; MICROSOMAL TRANSPORT PROTEIN; MICROSOMAL TRANSPORT PROTEIN INHIBITOR; MIPOMERSEN; NARINGENIN; OMEGA 3 FATTY ACID; PLACEBO; PROTEIN INHIBITOR; RETINOL; SLX 4090; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NEW DRUG;

ABETALIPOPROTEINEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FOOD COMPOSITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONVIRAL GENE THERAPY; OBESITY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN ASSEMBLY; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPEATED DRUG DOSE; REVIEW; RISK MANAGEMENT; RNA INTERFERENCE; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; LIVER; METABOLISM; PHYSIOLOGY;

ABETALIPOPROTEINEMIA; ANIMALS; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; HYPERTRIGLYCERIDEMIA; LIVER; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; TRIGLYCERIDES;

EID: 69149090880     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340703     Document Type: Review

References (111)

1. Menotti A, Keys A, Aravanis C, Blackburn H, Dontas A, Fidanza F, et al. Seven countries study: first 20-year mortality data in 12 cohorts of six countries. Ann Med 1989; 21(3): 175-9.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-52.
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): S1-113.
5. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (suppl V): v1-v52.
6. Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WB, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003; 19(3): 155-68.
7. Wierzbicki AS. A fishy business: omega-3 fatty acids and cardiovascular disease. Int J Clin Pract 2008; 62(8): 1142-6.
8. Ansell BJ. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr Atheroscler Rep 2005; 7(1): 29-33.
9. Wierzbicki AS. Low HDL-cholesterol: Common and under-treated, but which drug to use? Int J Clin Pract 2006; 60(10): 1149-53.
10. Mukhtar RY, Reckless JP. Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol 2005; 16(6): 640-7.
11. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115(4): 450-8.
12. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008; 10(5): 386-90.
13. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70(7): 733-7.
14. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2(3): 200-7.
15. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernand PM, Despies, JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25(3): 553-9.
16. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implication Dagenais GR s for treatment. Circulation 1992; 85(1): 37-45.
17. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285(12): 1585-91.
18. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165(10): 1154-60.
19. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20(8): 1253-68.
20. Athyros VG, Kakafika AI, Papageorgiou AA, Tziomalos K, Skaperdas A, Pagourelias E, et al. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007; 42(11): 999-1009.
21. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90(2):139-43.
22. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99(1): 95-112.
23. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111(3): 185-91.
24. Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006; 99(5): 277-87.
25. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins vs lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361(9359):777-80.
26. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85(5): 544-8.
27. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 2001; 1(5):327-36.
28. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007; 100(11 A): S53-S61.
29. Wierzbicki AS. Lipid-altering agents: the future. Int J Clin Pract 2004; 58(11): 1063-72.
30. Wetterau JR, Gregg RE, Harrity TW, Arbeeny C, Cap M, Connolly F, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282(5389): 751-4.
31. Shoulders CC, Shelness GS. Current biology of MTP: implications for selective inhibition. Curr Top Med Chem 2005; 5(3):283-300.
32. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356(2): 148-56.
33. Davidson NO, Shelness GS. Apolipo Protein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-93.
34. Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 1987; 238(4825): 363-6.
35. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42(9): 1346-67.
36. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358(9298): 2026-33.
37. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298(7): 776-85.
38. 2 cells. J Biol Chem 2000; 275(6): 3950-6.
39. Ito MK. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense? Ann Pharmacother 2007; 41(10): 1669-78.
40. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005; 258(5): 395-410.
41. Chan DC, Barrett PH, Watts GF. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 2006; 17(1): 28-36.
42. Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta 2000; 1486(1): 72-83.
43. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44(1): 22-32.
44. Nielsen LB, Veniant M, Boren J, Raabe M, Wong JS, Tam C, et al. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 1998; 98(1): 13-6.
45. Levy E, Stan S, Delvin E, Menard D, Shoulders C, Garofalo C, et al. Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J Biol Chem 2002; 277(19): 16470-7.
46. Wang S, McLeod RS, Gordon DA, Yao Z. The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. J Biol Chem 1996; 271(24): 14124-33.
47. Du EZ, Wang SL, Kayden HJ, Sokol R, Curtiss LK, Davis RA. Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. J Lipid Res 1996; 37(6): 1309-15.
48. Du EZ, Fleming JF, Wang SL, Spitsen GM, Davis RA. Translocation-arrested apolipoprotein B evades proteasome degradation via a sterol-sensitive block in ubiquitin conjugation. J Biol Chem 1999; 274(3): 1856-62.
49. Mann CJ, Anderson TA, Read J, Chester SA, Harrison GB, Kochl S, et al. The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins. J Mol Biol 1999; 285(1): 391-408.
50. Bradbury P, Mann CJ, Kochl S, Anderson TA, Chester SA, Hancock JM, et al. A common binding site on the microsomal triglyceride transfer protein for apolipoprotein B and protein disulfide isomerase. J Biol Chem 1999; 274(5):3159-64.
51. Hussain MM, Bakillah A, Nayak N, Shelness GS. Amino acids 430-570 in apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein. J Biol Chem 1998; 273(40): 25612-5.
52. Dashti N, Gandhi M, Liu X, Lin X, Segrest JP. The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry 2002; 41(22): 6978-87.
53. Nielsen LB. Lipoprotein production by the heart: a novel pathway of triglyceride export from cardiomyocytes. Scand J Clin Lab Invest Suppl 2002; 237: 35-40.
54. Nielsen LB, Perko M, Arendrup H, Andersen CB. Microsomal triglyceride transfer protein gene expression and triglyceride accumulation in hypoxic human hearts. Arterioscler Thromb Vasc Biol 2002; 22(9): 1489-94.
55. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365(6441): 65-9.
56. Shoulders CC, Brett DJ, Bayliss JD, Narcisi TM, Jarmuz A, Grantham TT, et al. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet 1993; 2(12): 2109-16.
57. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Björkegren J, Nielsen LB, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 1999; 103(9): 1287-98.
58. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258(5084): 999-1001.
59. Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci 2005; 42(5-6): 515-45.
60. Ricci B, Sharp D, O'Rourke E, Kienzle B, Blinderman L, Gordon D, et al. A 30-amino acid truncation of the microsomal triglyceride transfer protein large subunit disrupts its interaction with protein disulfide-isomerase and causes abetalipoproteinemia. J Biol Chem 1995; 270(24): 14281-5.
61. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000; 20: 663-97.
62. Chowers I, Banin E, Merin S, Cooper M, Granot E. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye 2001; 15(Pt 4): 525-30.
63. Jamil H, Gordon DA, Eustice DC, Brooks CM, Dickson JK Jr, Chen Y, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci USA 1996; 93(21): 11991-5.
64. Liang J, Ginsberg HN. Microsomal triglyceride transfer protein binding and lipid transfer activities are independent of each other, but both are required for secretion of apolipoprotein B lipoproteins from liver cells. J Biol Chem 2001; 276(30): 28606-12.
65. Pan M, Liang JS, Fisher EA, Ginsberg HN. The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglyceride synthesis. J Biol Chem 2002; 277(6): 4413-21.
66. Arrol S, Mackness MI, Durrington PN. The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). Atherosclerosis 2000; 150(2): 255-64.
67. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46(6): 733-49.
68. Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res 2001; 42(5): 725-34.
69. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 2003; 52(10): 2554-61.
70. Borradaile NM, de Dreu LE, Barrett PH, Behrsin CD, Huff MW. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 2003; 42(5): 1283-91.
71. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005; 54(6): 1676-83.
72. Borradaile NM, de Dreu LE, Wilcox LJ, Edwards JY, Huff MW. Soya phytoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Biochem J 2002; 366(Pt 2): 531-9.
73. Lin MC, Wang EJ, Lee C, Chin KT, Liu D, Chiu JF, et al. Garlic inhibits microsomal triglyceride transfer protein gene expression in human liver and intestinal cell lines and in rat intestine. J Nutr 2002; 132(6): 1165-8.
74. Tietge UJ, Bakillah A, Maugeais C, Tsukamoto K, Hussain M, Rader DJ. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res 1999; 40(11): 2134-9.
75. Bakillah A, Nayak N, Saxena U, Medford RM, Hussain MM. Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist. Biochemistry 2000; 39(16): 4892-9.
76. Cardozo C, Wu X, Pan M, Wang H, Fisher EA. The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein b100. Biochemistry 2002; 41(31): 10105-14.
77. Chang G, Ruggeri RB, Harwood HJ, Jr. Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr Opin Drug Discov Devel 2002; 5(4): 562-70.
78. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78.
79. Wierzbicki AS, Graham CA, Young IS, et al. Familial combined hyperlipidaemia: under - defined and under - diagnosed? Curr Vasc Pharmacol 2008; 6(1): 13-22.
80. Sniderman AJ. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol 2008; 2(1): 36-42.
81. Tarugi P, Lonardo A, Ballarini G, Erspamer L, Tondelli E, Bertolini S, et al. A study of fatty liver disease and plasma lipoproteins in kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol 2000; 33(3): 361-70.
82. Whitfield AJ, Barrett PH, Robertson K, et al. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin Chem 2005; 51(1): 266-9.
83. Iqbal J, Dai K, Seimon T, Jungreis R, Oyadomari M, Kuriakose G, et al. IRE1b inhibits chylomicron production by selectively degrading MTP mRNA. Cell Metab 2008; 7(5): 445-55.
84. White DA, Bennett AJ, Billett MA, et al. The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein. Br J Nutr 1998; 80(3): 219-29.
85. Ros E. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000; 151(2): 357-79.
86. Kamstrup PR, Benn M, Tybaerg-Hansen A, et al. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117(2): 176-84.
87. Rana JS, Jansen AC, Zwinderman AH, van Aalst-Cohen ES, Jukema JW, Trip MD, et al. Lipoprotein (a) and risk of cardiovascular disease in patients with metabolic syndrome in a population of familial hypercholesterolaemia. J Intern Med 2006; 260(2): 183-5.
88. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein (a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89(8): 893-6.
89. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46(5): 872-84.
90. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004; 351(17): 1772-7.
91. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432(7014): 173-8.
92. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441(7089): 111-4.
93. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441(7092): 537-41.
94. Marsden PA. RNA interference as potential therapy - not so fast. N Engl J Med 2006; 355(9): 953-4.
95. Crooke RM. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther 2005; 5(7): 907-17.
96. Burnett JR. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 2006; 8(5): 461-7.
97. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114(16): 1729-35.
98. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44(10): 1887-901.
99. Samaha FF, McKenney J, Bloedon LT, et al. Efficacy and safety of MTP-inhibitor AEGR-733 as monotherapy and in combination with ezetimibe. [abstract]. J Clin Lipidol 2007; 1(5): 469.
100. Samaha FF, McKenney J, Bloedon LT, et al. MTP-Inhibitor, AEGR-733, reduces body weight in patients with hypercholesterolemia [abstract]. J Clin Lipidol 2007; 1(5): 477.
101. Ueshima K, kihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005; 28(2): 247-52.
102. Farnier M, Stein E, Megnien S, Ose L, van Mieghem W, Kastekin JJ, et al. Efficacy and safety of implitapide, a microsomal triglyceride protein inhibitor in patients with primary hypercholesterolemia. International Symposium on Drugs Affecting Liver Metabolism 2001.
103. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005; 5: 30.
104. Prince WJ, Tong W, Frekany J, et al. SLX-4090- repeat dose treatment with a novel enterocyte specific MTP inhibitor reduces post-prandial triglyceride response and lowers LDL-C in healthy volunteers. [Abstract]. J Clin Lipidol 2007; 1(5): 471.
105. Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007; 18(4): 397-400.
106. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007; 100(11 A): S53-S61.
107. Rava P, Ojakian GK, Shelness GS, Hussain MM. Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins. J Biol Chem 2006; 281(16): 11019-27.
108. Spann NJ, Kang S, Li AC, Chen AZ, Newberry EP, Davidson NO, et al. Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis. J Biol Chem 2006; 281(44): 33066-77.
109. Wierzbicki AS. Intervening on HDL-C: is it possible? Does it work? Int J Clin Pract 2007; 61(11): 1782-6.
110. Viljoen A, Wierzbicki AS. Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract 2008; 62(4): 518-20.
111. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 2008; 62(7): 981-7.